ClinConnect ClinConnect Logo
Search / Trial NCT05271344

Oral Immunonutrition With Synbiotics, Omega 3 and Vitamin D in Patients Undergoing Duodenopancreatectomy for Tumoral Lesion.

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Mar 4, 2022

Trial Information

Current as of July 25, 2025

Recruiting

Keywords

Synbiotics Omega 3 Vitamin D Probiotics Prebiotics

ClinConnect Summary

This clinical trial is looking at a special type of nutrition called synbioimmunonutrition, which combines beneficial bacteria (probiotics), omega-3 fatty acids (found in fish oil), and vitamin D. The goal is to see if this nutrition plan can help patients who are about to have surgery for pancreatic cancer (specifically a procedure called duodenopancreatectomy) recover better than if they follow the usual nutrition plan for a week before surgery. Researchers believe that this new approach could reduce complications and improve overall health after surgery.

To participate in this trial, patients need to be scheduled for a duodenopancreatectomy for a tumor. However, there are some important requirements: patients who have had certain types of pancreatic surgery before, those with severe health issues, or anyone who cannot eat by mouth may not be eligible. Participants will receive the special nutrition plan before their surgery and will be monitored to see how well it works in helping them recover. If you or a loved one is considering this trial, it's a chance to potentially benefit from an innovative approach to care during a challenging time.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All cases of duodenopancreatectomy for tumoral lesions.
  • Exclusion Criteria:
  • Distal or total pancreatectomies, as well as procedures for chronic pancreatitis
  • Patient refusal or inability to provide informed consent
  • Use of dietary supplements containing omega 3, pre- or probiotics within 15 days prior to protocol initiation
  • Severe cardiorespiratory or renal insufficiency
  • HIV
  • Cirrhosis Child-Pugh B-C
  • Inability to feed by mouth
  • Intestinal obstruction
  • Unresectable tumor or metastatic disease on preoperative work-up
  • Cardiac valvular pathology
  • Short bowell syndrome
  • Haemophilia
  • Known allergy or intolerance to fish oil, fish or shellfish, milk, soy or components of the products used
  • BMI \< 16kg/m2
  • Weight loss \> 15% in the last 6 months
  • Little or no food in the last 10 days
  • Hypercalcemia
  • Pregnancy, breastfeeding

About Centre Hospitalier Universitaire De Liege

The Centre Hospitalier Universitaire de Liège (CHU Liège) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, CHU Liège integrates cutting-edge scientific inquiry with clinical practice, fostering an environment that enhances the development of new therapies and medical interventions. With a multidisciplinary team of experienced researchers and healthcare professionals, the institution is dedicated to improving patient outcomes and contributing to the global body of medical knowledge. CHU Liège emphasizes collaboration with industry partners and academic institutions to drive excellence in clinical research and support the translation of findings into real-world applications.

Locations

Liège, , Belgium

Patients applied

0 patients applied

Trial Officials

Arnaud De Roover, Pr

Study Director

Centre Hospitalier Universitaire de Liege

Alain Pans, MD

Principal Investigator

Centre Hospitalier Universitaire de Liege

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials